linking the pathogenesis of Crohn’s disease with this inflammation pathway. The human monoclonal antibody ustekinumab blocks the biologic activity of IL-12 and IL-23 by inhibiting receptors of ...

The European Commission (EC) has approved ustekinumab for the treatment of moderately to severely active Crohn’s disease in ...

Johnson & Johnson (J&J) has announced that Stelara (ustekinumab) has been approved by the European Commission (EC) to treat ...

Crohn’s disease, and ulcerative colitis. STEQEYMA® is the sixth STELARA® biosimilar on the market in the United States. According to Celltrion, “STEQEYMA will be priced with a WAC list price ...

The overlap of biologics during medication switches is common in routine care of patients with IBD and isn’t linked to a ...

Bio-Thera Solutions and Dr. Reddy’s Laboratories SA announced that they had entered into commercialization and licensing agreements ...

Celltrion is introducing Steqeymaq (ustekinumab-stba), which is a biosimilar ... arthritis in adult and pediatric patients, as well as Crohn's disease and ulcerative colitis in adult patients.

JERSEY CITY, N.J., March 27, 2025 /PRNewswire/ -- Celltrion, Inc., today announced that STEQEYMA ® (ustekinumab-stba ... as well as Crohn's disease (CD) and ulcerative colitis (UC) in adult ...

South Korea’s Samsung Bioepis presented data, including the budget impact analysis on ustekinumab biosimilars’ cost savings ...